Psoriasis: Update Bulletin [January 2016]
Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of moderate to severe plaque psoriasis. Topics covered include opinions about ixekizumab (Eli Lilly) and if safety concerns related to anti-IL-17 mAbs could influence physician adoption; the potential role for brodalumab (AstraZeneca/Valeant) despite safety concerns; where in the treatment paradigm Cimzia (certolizumab pegol; UCB/Dermira) will be used considering its late entrance to the market; where KOLs believe RORyt inhibitors, such as VTP-43742 (Vitae Pharmaceuticals)will be used in the treatment paradigm; what concerns KOLs have about using anti-TNF biosimilars, and which programmes are KOLs most excited about?
Key Questions Answered in this Update Bulletin:
Will safety concerns related to anti-IL-17 mAbs influence physician adoption of Eli Lilly’s ixekizumab as a treatment for moderate to severe plaque psoriasis?
Following on from regulatory submissions in Europe and the US, do KOLs believe there is a role for AstraZeneca’s/Valeant’s brodalumab as a treatment for moderate to severe plaque psoriasis despite safety concerns?
As a late entrant to the moderate to severe plaque psoriasis treatment landscape, how do KOLs view Cimzia’s chances of success, and what could enable UCB/Dermira to differentiate this product versus other anti-TNF therapies?
If approved, where do KOLs believe Vitae Pharmaceuticals’ VTP-43742 (a novel, orally active RORyt inhibitor) will be used in the moderate to severe plaque psoriasis treatment paradigm?
With several more anti-TNF biosimilars emerging from late-stage development in Europe and the US, what concerns do KOLs have about using these products as treatments for moderate to severe plaque psoriasis, and which programmes are KOLs most excited about?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Key Questions Answered in this Update Bulletin:
Will safety concerns related to anti-IL-17 mAbs influence physician adoption of Eli Lilly’s ixekizumab as a treatment for moderate to severe plaque psoriasis?
Following on from regulatory submissions in Europe and the US, do KOLs believe there is a role for AstraZeneca’s/Valeant’s brodalumab as a treatment for moderate to severe plaque psoriasis despite safety concerns?
As a late entrant to the moderate to severe plaque psoriasis treatment landscape, how do KOLs view Cimzia’s chances of success, and what could enable UCB/Dermira to differentiate this product versus other anti-TNF therapies?
If approved, where do KOLs believe Vitae Pharmaceuticals’ VTP-43742 (a novel, orally active RORyt inhibitor) will be used in the moderate to severe plaque psoriasis treatment paradigm?
With several more anti-TNF biosimilars emerging from late-stage development in Europe and the US, what concerns do KOLs have about using these products as treatments for moderate to severe plaque psoriasis, and which programmes are KOLs most excited about?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
